Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric ( mouse/ human) |
Target | α5β1 integrin |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6434H9942N1706O2040S52 |
Molar mass | 145501.33 g·mol−1 |
(what is this?) (verify) |
Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin. [1]
It is thought to reduce metastases. Early results show potential in renal cell cancers.[ citation needed]